Proactive - Interviews for investors

Proactive
  • 0.0 (0)
  • INVESTING
  • UPDATED DAILY

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

  1. 20 HR AGO

    NanoViricides files for Rare Pediatric Disease Designation for Measles Drug

    NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce that the company has filed an application for Rare Pediatric Disease Drug Designation with the U.S. FDA’s Office of Orphan Products Development for NV-387 as a treatment for measles. The RPDD application is expected to be combined with the company’s previously submitted Orphan Drug Designation application for NV-387, filed in February 2026, as part of a broader regulatory strategy to advance the drug candidate. If granted, the designation would make NanoViricides eligible for a Priority Review Voucher upon approval of NV-387. PRVs are tradable assets that have recently commanded values of approximately $160 million, reflecting their ability to accelerate regulatory review timelines for other drugs. Diwan emphasized the potential impact of NV-387, stating the therapy could become an important tool in addressing the resurgence of measles in the United States and globally. He added that treatment with NV-387 may support rapid recovery while helping to reduce complications, including the rare but serious post-measles “immune amnesia” effect. Currently, there are no approved antiviral treatments specifically for measles, highlighting a significant unmet medical need. The Rare Pediatric Disease Priority Review Voucher program was reauthorized in February 2026 under the Consolidated Appropriations Act, reinforcing incentives for companies developing therapies targeting serious pediatric conditions. Measles cases have been rising in the United States, with more than 1,600 laboratory-confirmed cases reported across 33 states as of early April 2026, according to the CDC. While hospitalization rates have declined compared to 2025, the disease continues to pose risks, particularly among pediatric populations, which account for approximately 70% of cases. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #measles #nanoviricides #NV387 #OrphanDrugDesignation #AntiviralTherapy #ClinicalTrials #PhaseII #OrphanDrugDesignation #FDA #Measles #Antiviral #HealthcareInnovation #MedicalResearch #Biopharma #PediatricHealth #GlobalHealth

    5 min

  2. 20 HR AGO

    Delta earnings and strong travel demand point to airline ETF opportunity

    U.S. Global Investors CEO Frank Holmes joined Steve Darling from Proactive to discuss the strength of global travel demand and what it means for airline investments and the Jets ETF. Holmes highlighted that despite ongoing geopolitical tensions and rising fuel costs, the airline industry continues to perform strongly, pointing to record quarterly revenue reported by Delta Air Lines as a key example. He described the sector’s performance as a positive signal for the broader economy, noting, “It’s like the canary in the coal mine, but in a good way… global travel demand is just strong.” Airlines have been able to pass on higher ticket prices while maintaining robust demand, supported by increased global mobility in the post-pandemic environment. The discussion also explored evolving travel patterns, including strong north-south traffic between North America and Latin America, as well as rising activity across Asia. Holmes pointed to the growing influence of digital nomads and seasonal travelers, who are helping drive bookings beyond pre-pandemic levels. He also highlighted a competitive advantage held by Delta, noting that its ownership of a refinery helps manage fuel costs and protect margins during periods of oil price volatility. Beyond airlines, Holmes emphasized continued strength in adjacent sectors such as cruise travel and cargo shipping, suggesting that the “underlying belly of the global economy remains pretty strong.” Looking ahead, he expressed optimism that geopolitical disruptions will prove temporary, while global travel demand continues its upward trajectory—supporting long-term opportunities in airline equities and ETFs such as the U.S. Global Jets ETF (JETS). #proactiveinvestors #usglobalinvestorsinc #nasdaq #TravelETFs #JETS #TRIPETF #FrankHolmes #USGlobalInvestors #AirlineStocks #CruiseStocks #SmartBeta #TravelBoom #ProactiveInvestors #USGlobalInvestors #FrankHolmes #TRIPETF #TravelStocks #CruiseStocks #AirlineETF #TravelTrends #PostCovidTravel #StockMarketInsights #ETFInvesting #CruiseBoom #AirlineDemand

    5 min

  3. 23 HR AGO

    TNR Gold chair on Altius C$4.2M investment, Mariana royalty flow, Los Azules & Shotgun projects

    TNR Gold Corp (TSX-V:TNR, FRA:TNW, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest strategic milestone following a C$4.2 million investment from Altius Minerals, a major Canadian royalty company. Klip described the investment as a strong endorsement of TNR Gold’s long-term strategy, noting that Altius has taken a non-control position of 23.5 million shares. He said: “It’s a strategic non-control position that signals confidence in our company,” highlighting the significance of backing from a well-established player in the mining royalty sector. The announcement triggered a strong market response, with TNR Gold’s share price rising 30% following the news. Klip pointed to this as validation of the company’s corporate development strategy and growing recognition of its royalty portfolio. He also outlined how the investment strengthens TNR Gold’s financial position, enabling it to advance its goal of becoming a leading green energy metals royalty and gold company. The company is now focused on expanding its royalty holdings and delivering shareholder returns through potential buybacks and future dividends. Looking ahead, Klip noted that TNR Gold expects to begin receiving royalty payments in the near term, supported by production progress at its Mariana Lithium project, while continued developments at Los Azules and other assets provide additional upside. For more updates like this, visit Proactive’s YouTube channel, give the video a like, subscribe, and enable notifications so you never miss new content. #TNRGold #AltiusMinerals #MiningStocks #RoyaltyCompanies #GoldStocks #Lithium #Copper #JuniorMining #InvestingNews #StockMarket #MiningInvestment #EnergyTransition #ResourceStocks

    6 min

  4. 1 DAY AGO

    Rome Resources CEO on strongest tin intercepts yet at Kalayi

    Rome Resources Plc (AIM:RMR, FRA:33R) CEO Paul Barrett talked with Proactive's Stephen Gunnion about the company’s latest drilling results from the Kalayi prospect in the Democratic Republic of Congo, highlighting what he described as the strongest intercepts achieved to date. Barrett explained that the recent campaign, which covered over 3,000 metres of drilling, focused largely on Kalayi and delivered significantly wider intercepts than previously seen. He noted that “5 or 6 of the holes in this sequence have been much, much better… in terms of the widths of the intercepts,” pointing to encouraging signs for the project’s scale. The company has been targeting deeper extensions of previously identified mineralisation, with early XRF readings suggesting strong continuity. While Barrett cautioned that these results remain semi-quantitative until lab assays are confirmed, he expressed confidence that the increased widths should provide a reliable indication of overall mineralisation. Importantly, new intercepts in previously untested areas could expand the footprint of the deposit. Barrett said this “could increase the footprint quite a lot,” adding that mineralisation remains open at depth, presenting further exploration upside. Looking ahead, Rome Resources is assessing next steps, including potential drilling strategies to access deeper zones more efficiently. The proximity of Kalayi to the Alphamin operation - just eight kilometres away - also provides a clear pathway toward potential development and commercialisation. For more updates like this, visit Proactive’s YouTube channel, give this video a like, subscribe, and enable notifications so you never miss future content. #RomeResources #PaulBarrett #Kalayi #TinMining #DrillingResults #MiningExploration #ResourceGrowth #XRF #MiningNews #ProactiveInvestors

    4 min

  5. 1 DAY AGO

    Fineqia International's Matteo Greco on Q1 crypto ETP trends, Q2 outlook

    Fineqia International Inc (CSE:FNQ) senior associate Matteo Greco talked with Proactive's Stephen Gunnion about the latest trends shaping crypto markets in Q1 2026, highlighting how geopolitical tensions and macroeconomic uncertainty are influencing investor behaviour. Greco explained that Bitcoin continues to dominate institutional allocations, now accounting for over 81% of total crypto ETP assets under management. He noted, "BTC represents the equivalent of a safe haven in terms of crypto," as investors shift away from more volatile assets during periods of heightened uncertainty. This risk-off sentiment has been driven by geopolitical developments, including tensions involving Iran and the US, as well as concerns around inflation and potential stagflation. The discussion also explored why Ethereum has seen negative ETP flows despite price gains, with Greco attributing this to profit-taking following a strong 2025 and broader caution in the altcoin market. Meanwhile, basket ETPs have underperformed significantly, reflecting their exposure to smaller, less liquid assets that are more vulnerable during downturns. Looking ahead, Greco suggested that the next few weeks will be critical in determining the trajectory for Q2 2026, particularly as markets assess the impact of rising oil prices and evolving geopolitical risks. Despite recent market weakness, the continued growth in ETP listings signals long-term confidence in the sector. For more expert insights and market updates, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss future content. #Bitcoin #CryptoMarket #Ethereum #CryptoETP #Investing #DigitalAssets #BTC #CryptoNews #MarketOutlook #Blockchain #InstitutionalInvestors #RiskOff #CryptoTrends

    8 min

  6. 1 DAY AGO

    King Ridge Capital CEO on benefits and strategy of KRC Cat Bond UCITS ETF

    King Ridge Capital Inc CEO Rick Pagnani talked with Proactive's Stephen Gunnion about the KRC Cat Bond UCITS ETF (CATB), explaining how catastrophe bonds work and why they can play a valuable role in diversified portfolios. Pagnani outlined that cat bonds are insurance-linked securities that allow insurers to transfer risk to capital markets. These instruments are “fully collateralised and decoupled from the insurance company,” offering investors exposure that is largely uncorrelated to traditional equity and credit markets. He highlighted that this low correlation is a key differentiator, noting that cat bonds “serve to dampen volatility and increase return.” The discussion also explored portfolio construction, with King Ridge Capital focusing on diversification across regions, perils, and issuers to build resilience against single catastrophic events. Pagnani emphasised the importance of risk management and liquidity, ensuring the portfolio can withstand shocks while maintaining steady income through coupon payments. The interview touched on real-world events, including the impact of the LA wildfires, where the broader cat bond market showed resilience, recovering quickly and delivering an annual return of over 11%. Pagnani also addressed investor allocation, suggesting cat bonds can represent around 5–10% of a portfolio, and explained why the ETF’s fee structure reflects the complexity of underwriting and modelling these instruments. For investors seeking yield, diversification, and reduced correlation to traditional markets, he said CATB presents a compelling option. For more insights like this, visit Proactive’s YouTube channel, give this video a like, subscribe, and enable notifications so you never miss an update. #CatBonds #ETFInvesting #FixedIncome #PortfolioDiversification #KingRidgeCapital #CATB #InsuranceLinkedSecurities #AlternativeInvestments #YieldInvesting #RiskManagement #InvestingStrategy #FinanceInsights

    7 min

  7. 1 DAY AGO

    EnWave signs R&D license agreement with Rhizome Food and Farming

    EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to discuss the company’s newly signed Research and Development License Agreement (RDLA) with Rhizome Food and Farming, a North American food company led by renowned chef Dan Barber, a recipient of multiple Michelin stars. Charleton explained that the agreement builds on prior engagement involving Row 7, which, through its connection to Barber, had entered into a rental arrangement for a small-scale 3.6kW Radiant Energy Vacuum (REV™) dehydration machine. That equipment supported the development of innovative, chef-driven food products. Row 7 is not affiliated with Rhizome, but the company has since purchased the 3.6kW REV™ system to continue advancing commercial product development. Under the RDLA, Rhizome gains broad rights to use EnWave’s REV™ technology for research and development purposes. This includes collaboration with third-party food and agriculture companies on product and process innovation, as well as the production of limited volumes of commercial product for market trials. With this agreement, Rhizome joins EnWave’s global network of R&D partners, which includes leading institutions such as Cornell University, the Danish Technological Institute, Queensland University of Technology (QUT) in Australia, and CNTA in Spain. These partners utilize REV™ equipment to collaborate with EnWave, applying vacuum-microwave dehydration technology to solve product-specific challenges and accelerate innovation. Rhizome plans to use REV™ technology as a core component of its culinary and agricultural research ecosystem, exploring “moonshot” ideas in shelf stability, nutrient density, and flavor. The initiative will draw on its extensive network of chefs, scientists, and industry collaborators while helping to de-risk future commercialization opportunities. #proactiveinvestors #enwavecorporation #tsxv #enw #REVTechnology #FoodInnovation #AgriTech #DehydrationTech #RAndD #FoodScience #SustainableFood #CleanTech #CulinaryInnovation #FoodProcessing #AgInnovation #ProductDevelopment #FoodTech #Innovation

    3 min

  8. 1 DAY AGO

    Coiled Therapeutics doubles cancer drug's success rate with simple dosing change

    Coiled Therapeutics (AIM:COIL) executive chair Dr Sotirios Stergiopoulos and CEO Sridhar Vempati talked with Proactive's Stephen Gunnion about promising clinical results for its lead oncology candidate AO-252. The discussion highlighted a significant improvement in clinical outcomes, with the company reporting an increase in clinical benefit rate from 40% to 80% following a shift to twice-daily dosing. Vempati explained that the enhanced efficacy appears linked to sustained drug exposure, noting that maintaining therapeutic levels for longer durations helps drive stronger results. He also emphasized AO-252’s multimodal mechanism, targeting mitosis, DNA damage repair, and immune activation. This approach not only attacks tumors directly but may also help the immune system recognize and respond to cancer more effectively. Stergiopoulos highlighted the importance of these findings in heavily pre-treated patients, many of whom had exhausted available treatment options. He said: “The fact that we’re seeing effect is really astounding… and it gives us every confidence that we are on the right path.” The ability to generate responses in such late-stage cases suggests potential for even greater efficacy in earlier treatment lines. The company is now advancing plans for combination trials and new formulations, with multiple data readouts expected throughout 2026. AO-252’s favorable safety profile and synergy with existing therapies could expand its use across a wide range of cancer indications. For more insights like this, visit Proactive’s YouTube channel, give this video a like, subscribe, and turn on notifications so you never miss an update. #CoiledTherapeutics #AO252 #CancerResearch #Oncology #Biotech #ClinicalTrials #DrugDevelopment #Immunotherapy #CancerTreatment #HealthcareInnovation #Biopharma #PrecisionMedicine

    9 min
See All (601)

About

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

Information

You Might Also Like